New biobank aims to unlock secrets of lung scarring diseases
NCT ID NCT05392881
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This study is creating a registry and biobank for up to 1,000 people with interstitial lung diseases, including sarcoidosis and pulmonary fibrosis. Researchers will collect medical data and biological samples over time to help future studies. The goal is to better understand these lung conditions, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this biobank could help researchers better understand interstitial lung diseases and point toward new treatments.
What could go wrong
This is an observational biobank study, not a treatment trial. It does not test any therapy, so it cannot directly lead to a cure or symptom relief.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.